As part of a push to increase competition and lower drug prices, the U.S. Senate recently passed a bill that limits the number of patents that can be asserted in biosimilar litigation. The Affordable Prescriptions for Patients Act of 2023 (S.150) mandates that a maximum of 20 patents — with some exceptions — can be asserted against a biosimilar competitor in a Biologics Price Competition and Innovation Act (BPCIA) action.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Jonathan
Contact Jonathan, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack